Send this to a friend

After Nasdaq woes, RXi pivots to promising cancer treatment field

In 1998, Craig C. Mello, a biologist at University of Massachusetts Medical School, and his colleague, Andrew Z. Fire, discovered a natural process known as RNA interference (or RNAi) that can be harnessed to make tiny, targeted changes in the way our genes transform our bodies. After winning the Nobel Prize for the discovery in 2006, Mello went on to cofound RXi Pharmaceuticals, where he now serves as chair of the Scientific Advisory Board.
In the ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media